CHOSA Oncology AB payback of convertible loan in process

Apr 18, 2023

CHOSA Oncology AB has initiated the process of payback of the convertible loan of 14,98 mSEK (plus interest) which RhoVac obtained from shareholders to support the development of RV001 and which will be balanced by the EU grant from Horizon 2020. The process is unfortunately more complex than anticipated, which causes a delay. The payback is in process, and we expect to have it concluded within the coming week(s)

CEO Peter Buhl comments: “The initiation process in ongoing but has unfortunately caused us more administrative challenges than we had hoped for. I want to apologize for any inconvenience this may cause and again thank you all for your patience.”

This disclosure contains information that Chosa Oncology AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-04-2023 14:45 CET.